Cargando…

Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan

BACKGROUND AND AIMS: Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Smagul, Manar, Esmagambetova, Aizhan, Nusupbaeva, Gauhar, Kirpicheva, Ulyana, Kasabekova, Lena, Nukenova, Gauhar, Saliev, Timur, Fakhradiyev, Ildar, Tanabayeva, Shynar, Zhussupov, Baurzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921938/
https://www.ncbi.nlm.nih.gov/pubmed/35317419
http://dx.doi.org/10.1002/hsr2.562
_version_ 1784669421750452224
author Smagul, Manar
Esmagambetova, Aizhan
Nusupbaeva, Gauhar
Kirpicheva, Ulyana
Kasabekova, Lena
Nukenova, Gauhar
Saliev, Timur
Fakhradiyev, Ildar
Tanabayeva, Shynar
Zhussupov, Baurzhan
author_facet Smagul, Manar
Esmagambetova, Aizhan
Nusupbaeva, Gauhar
Kirpicheva, Ulyana
Kasabekova, Lena
Nukenova, Gauhar
Saliev, Timur
Fakhradiyev, Ildar
Tanabayeva, Shynar
Zhussupov, Baurzhan
author_sort Smagul, Manar
collection PubMed
description BACKGROUND AND AIMS: Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim of this study was to determine the sero‐prevalence of SARS‐CoV‐2 in the main cities of Kazakhstan. METHODS: The research was conducted as a cluster‐randomized cross‐sectional national household study in three cities of Kazakhstan. The study covered the period: from October 24, 2020, to January 11, 2021. A total of 5739 people took part in the study. All participants agreed to be tested for antibodies to IgM/IgG. Demographic characteristics were analyzed. The presence of symptoms of respiratory diseases and the results of polymerase chain reaction (PCR) testing were determined. The antibodies to the SARS‐CoV‐2 virus were detected using the method of enzyme‐linked immunosorbent assay (ELISA). RESULTS: There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS‐CoV‐2 in Almaty 57.0%, in Oskemen 60.7% than in Kostanay 39.4%. There were no significant differences in prevalence between men and women (p ≥ 0.05). In Almaty, only 19% of participants with antibodies reported the presence of respiratory symptoms during a pandemic. At the same time, the percentage of patients with antibodies who had respiratory symptoms was 36% in Oskemen and 27% in Kostanay. CONCLUSION: The findings indicate that despite reasonable level of seroprevalence, the country has not yet reached the baseline minimum of herd immunity scores. The prevalence estimates for asymptomatic or subclinical forms of the disease ranged from 64% to 81%. Thus, given that almost half of the population of Kazakhstan remains vulnerable, the importance of preventive strategies such as social distancing, the use of medical masks, and vaccination to protect the population from the transmission of SARS‐CoV‐2 is highly critical.
format Online
Article
Text
id pubmed-8921938
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89219382022-03-21 Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan Smagul, Manar Esmagambetova, Aizhan Nusupbaeva, Gauhar Kirpicheva, Ulyana Kasabekova, Lena Nukenova, Gauhar Saliev, Timur Fakhradiyev, Ildar Tanabayeva, Shynar Zhussupov, Baurzhan Health Sci Rep Original Research BACKGROUND AND AIMS: Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim of this study was to determine the sero‐prevalence of SARS‐CoV‐2 in the main cities of Kazakhstan. METHODS: The research was conducted as a cluster‐randomized cross‐sectional national household study in three cities of Kazakhstan. The study covered the period: from October 24, 2020, to January 11, 2021. A total of 5739 people took part in the study. All participants agreed to be tested for antibodies to IgM/IgG. Demographic characteristics were analyzed. The presence of symptoms of respiratory diseases and the results of polymerase chain reaction (PCR) testing were determined. The antibodies to the SARS‐CoV‐2 virus were detected using the method of enzyme‐linked immunosorbent assay (ELISA). RESULTS: There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS‐CoV‐2 in Almaty 57.0%, in Oskemen 60.7% than in Kostanay 39.4%. There were no significant differences in prevalence between men and women (p ≥ 0.05). In Almaty, only 19% of participants with antibodies reported the presence of respiratory symptoms during a pandemic. At the same time, the percentage of patients with antibodies who had respiratory symptoms was 36% in Oskemen and 27% in Kostanay. CONCLUSION: The findings indicate that despite reasonable level of seroprevalence, the country has not yet reached the baseline minimum of herd immunity scores. The prevalence estimates for asymptomatic or subclinical forms of the disease ranged from 64% to 81%. Thus, given that almost half of the population of Kazakhstan remains vulnerable, the importance of preventive strategies such as social distancing, the use of medical masks, and vaccination to protect the population from the transmission of SARS‐CoV‐2 is highly critical. John Wiley and Sons Inc. 2022-03-15 /pmc/articles/PMC8921938/ /pubmed/35317419 http://dx.doi.org/10.1002/hsr2.562 Text en © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Smagul, Manar
Esmagambetova, Aizhan
Nusupbaeva, Gauhar
Kirpicheva, Ulyana
Kasabekova, Lena
Nukenova, Gauhar
Saliev, Timur
Fakhradiyev, Ildar
Tanabayeva, Shynar
Zhussupov, Baurzhan
Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title_full Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title_fullStr Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title_full_unstemmed Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title_short Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
title_sort sero‐prevalence of sars‐cov‐2 in certain cities of kazakhstan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921938/
https://www.ncbi.nlm.nih.gov/pubmed/35317419
http://dx.doi.org/10.1002/hsr2.562
work_keys_str_mv AT smagulmanar seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT esmagambetovaaizhan seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT nusupbaevagauhar seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT kirpichevaulyana seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT kasabekovalena seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT nukenovagauhar seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT salievtimur seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT fakhradiyevildar seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT tanabayevashynar seroprevalenceofsarscov2incertaincitiesofkazakhstan
AT zhussupovbaurzhan seroprevalenceofsarscov2incertaincitiesofkazakhstan